Denver, CO – According to filings with the U.S. Securities and Exchange Commission, Cerecin is raising $30,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Charles Stacey played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cerecin
Cerecin is a global healthcare company with almost 20 years of innovation and leadership in brain health. At Cerecin we think differently. We develop novel evidence-based solutions that help people; pharmaceuticals, medical foods, diagnostics, medical devices and e-health products. These solutions target conditions ranging from memory impairment to some of the most devastating neurological diseases. The development of neurotherapeutics is the next frontier in biomedical science. Our understanding of the core molecular and cellular processes that contribute to brain development, plasticity, function, and aging is witnessing a revolution. This dramatic progress is leading to a paradigm change in the development of therapeutics for some of the most debilitating neurological conditions.

To learn more about Cerecin, visit http://www.cerecin.com/

Contact:
Charles Stacey, President and Chief Executive Officer
303-999-3700
cstacey@cerecin.com
https://www.linkedin.com/in/cstacey/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved